Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review)
- Authors:
- Chun Wei
- Xiaojun Lan
- Maona Qiu
- Ran Cui
- Qiuxia Fu
- Shafiu A. Umar Shinge
- Tobias Achu Muluh
- Ou Jiang
-
Affiliations: Department of Oncology, The Second People's Hospital of Neijiang City, Neijiang, Sichuan 641000, P.R. China, Department of Oncology, The First People's Hospital of Neijiang City, Neijiang, Sichuan 641000, P.R. China, Department of General Medicine, The People's Hospital of Luzhou City, Luzhou, Sichuan 646000, P.R. China, Department of Cardiothoracic Surgery, Sun Yat Sen Memorial Hospital, Sun Yat Sen University, Guangzhou, Guangdong 510080, P.R. China, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong 518060, P.R. China - Published online on: July 17, 2023 https://doi.org/10.3892/ol.2023.13958
- Article Number: 372
-
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Shonka DC Jr, Ho A, Chintakuntlawar AV, Geiger JL, Park JC, Seetharamu N, Jasim S, Abdelhamid Ahmed AH, Bible KC, Brose MS, et al: American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head Neck. 44:1277–1300. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Guo Y: Therapy of head and neck cancer in China: Introduction to the special issue. Head Neck. 44:2007–2008. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Lahtinen S, Nurkkala J, Hannula S, Ohtonen P, Koivunen P and Liisanantti JH: Perioperative risk factors for one-year mortality in patients with free-flap reconstruction due to cancer of the head and neck. J Oral Maxillofac Surg. 79:1384.e1–1384.e5. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Marziliano A, Teckie S and Diefenbach MA: Alcohol-related head and neck cancer: Summary of the literature. Head Neck. 42:732–738. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ward G, Mehta V and Moore M: Morbidity, mortality and cost from HPV-related oropharyngeal cancer: Impact of 2-, 4- and 9-valent vaccines. Hum Vaccin Immunother. 12:1343–1347. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Mehanna H, Paleri V, West CM and Nutting C: Head and neck cancer-Part 1: Epidemiology, presentation, and prevention. BMJ. 341:c46842010. View Article : Google Scholar : PubMed/NCBI | |
|
Ravikumar S, Casellas NJ, Shah S and Rieth K: Geographic disparities in head and neck cancer survival in Upstate New York 2011–2019. Head Neck. 44:472–482. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Andisheh-Tadbir A, Mehrabani D and Heydari ST: Epidemiology of squamous cell carcinoma of the oral cavity in Iran. J Craniofac Surg. 19:1699–1702. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Shehan JN, Alwani T, LeClair J, Mahoney TF, Agarwal P, Chaudhry ST, Wang JJ, Noordzij JP, Tracy LF, Edwards HA, et al: Social determinants of health and treatment decisions in head and neck cancer. Head Neck. 44:372–381. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Lee T, Cho J, Baek CH, Son YI, Jeong HS, Chung MK, Hong SD, Ahn YC, Oh DR, Noh JM, et al: Prevalence of NUT carcinoma in head and neck: Analysis of 362 cases with literature review. Head Neck. 42:924–938. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yang TH, Xirasagar S, Cheng YF, Wu CS, Kao YW, Shia BC and Lin HC: Association between pioglitazone use and head and neck cancer: Population-based case-control study. Head Neck. 42:653–659. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ling Z, Cheng B and Tao X: Epithelial-to-mesenchymal transition in oral squamous cell carcinoma: Challenges and opportunities. Int J Cancer. 148:1548–1561. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Cramer JD, Burtness B, Le QT and Ferris RL: The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 16:669–683. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Saada-Bouzid E, Peyrade F and Guigay J: Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck. Curr Opin Oncol. 31:146–151. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Mei Z, Huang J, Qiao B and Lam AK: Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. Int J Oral Sci. 12:162020. View Article : Google Scholar : PubMed/NCBI | |
|
Powell SF, Gold KA, Gitau MM, Sumey CJ, Lohr MM, McGraw SC, Nowak RK, Jensen AW, Blanchard MJ, Fischer CD, et al: Safety and efficacy of Pembrolizumab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: A Phase IB study. J Clin Oncol. 38:2427–2437. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Qureshi HA and Lee SM: Immunotherapy approaches beyond PD-1 inhibition: The future of cellular therapy for head and neck squamous cell carcinoma. Curr Treat Options Oncol. 20:312019. View Article : Google Scholar : PubMed/NCBI | |
|
Abbott M and Ustoyev Y: Cancer and the immune system: The history and background of immunotherapy. Semin Oncol Nurs. 35:1509232019. View Article : Google Scholar : PubMed/NCBI | |
|
Cillo AR, Kürten CHL, Tabib T, Qi Z, Onkar S, Wang T, Liu A, Duvvuri U, Kim S, Soose RJ, et al: Immune landscape of Viral- and Carcinogen-driven head and neck cancer. Immunity. 52:183–199.e9. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cramer JD, Burtness B and Ferris RL: Immunotherapy for head and neck cancer: Recent advances and future directions. Oral Oncol. 99:1044602019. View Article : Google Scholar : PubMed/NCBI | |
|
Taberna M, Oliva M and Mesía R: Cetuximab-Containing combinations in locally advanced and recurrent or metastatic head and neck squamous cell carcinoma. Front Oncol. 9:3832019. View Article : Google Scholar : PubMed/NCBI | |
|
Elbers JBW, Al-Mamgani A, Tesseslaar MET, van den Brekel MWM, Lange CAH, van der Wal JE, Verheij M, Zuur CL and de Boer JP: Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial. Radiother Oncol. 142:79–84. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Iovoli AJ, Hermann GM, Ma SJ, Platek AJ, Farrugia MK, Yau E, Wooten KE, Arshad H, Gupta V, Kuriakose MA, et al: Association of Nonsteroidal Anti-inflammatory drug use with survival in patients with squamous cell carcinoma of the head and neck treated with chemoradiation therapy. JAMA Netw Open. 3:e2071992020. View Article : Google Scholar : PubMed/NCBI | |
|
Wei T, Leisegang M, Xia M, Kiyotani K, Li N, Zeng C, Deng C, Jiang J, Harada M, Agrawal N, et al: Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma. Oncoimmunology. 10:19297262021. View Article : Google Scholar : PubMed/NCBI | |
|
Wilson HL, D'Agostino RB Jr, Meegalla N, Petro R, Commander S, Topaloglu U, Zhang W and Porosnicu M: The prognostic and therapeutic value of the mutational profile of blood and tumor tissue in head and neck squamous cell carcinoma. Oncologist. 26:e279–e89. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Cohen N, Fedewa S and Chen AY: Epidemiology and demographics of the head and neck cancer population. Oral Maxillofac Surg Clin North Am. 30:381–395. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Nooreldeen R and Bach H: Current and future development in lung cancer diagnosis. Int J Mol Sci. 22:86612021. View Article : Google Scholar : PubMed/NCBI | |
|
Hommel DJ, Brown ML and Kinzie JJ: Response to radiotherapy of head and neck tumors in AIDS patients. Am J Surg. 154:443–446. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Wilson RE: Surgical oncology. Cancer. 54 (Suppl 11):S2595–S2598. 1984. View Article : Google Scholar | |
|
Pagedar NA, Kendell N, Christensen AJ, Thomsen TA, Gist M and Seaman AT: Head and neck cancer survivorship from the patient perspective. Head Neck. 42:2431–2439. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Vincent AG, Wang W, Shokri T and Ducic Y: Treatment of oligometastatic disease in squamous cell carcinoma of the head and neck. Laryngoscope. 131:E1476–E1480. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Carron J, Torricelli C, Silva JK, Queiroz GSR, Ortega MM, Lima CSP and Lourenço GJ: microRNAs deregulation in head and neck squamous cell carcinoma. Head Neck. 43:645–667. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Philips R, Han C, Swendseid B, Curry J, Argiris A, Luginbuhl A and Johnson J: Preoperative immunotherapy in the multidisciplinary management of oral cavity cancer. Front Oncol. 11:6820752021. View Article : Google Scholar : PubMed/NCBI | |
|
Voortman J: Chemoradiotherapy plus a SMAC mimetic for locally advanced squamous cell carcinoma of the head and neck. Lancet Oncol. 21:1126–1128. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Botticelli A, Cirillo A, Strigari L, Valentini F, Cerbelli B, Scagnoli S, Cerbelli E, Zizzari IG, Rocca CD, D'Amati G, et al: Anti-PD-1 and Anti-PD-L1 in head and neck cancer: A network meta-analysis. Front Immunol. 12:7050962021. View Article : Google Scholar : PubMed/NCBI | |
|
Deschuymer S, Nevens D, Duprez F, Daisne JF, Dok R, Laenen A, Voordeckers M, De Neve W and Nuyts S: Randomized clinical trial on reduction of radiotherapy dose to the elective neck in head and neck squamous cell carcinoma; update of the long-term tumor outcome. Radiother Oncol. 143:24–29. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Irfan M, Delgado RZR and Frias-Lopez J: The oral microbiome and cancer. Front Immunol. 11:5910882020. View Article : Google Scholar : PubMed/NCBI | |
|
Huang SH and O'Sullivan B: Overview of the 8th Edition TNM classification for head and neck cancer. Curr Treat Options Oncol. 18:402017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou K, Li Y, Liao W, Zhang M, Bai L and Li Q: Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective. Oral Oncol. 107:1047542020. View Article : Google Scholar : PubMed/NCBI | |
|
Kreimer AR, Clifford GM, Boyle P and Franceschi S: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol Biomarkers Prev. 14:467–475. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zilberg C, Lee MW, Kraitsek S, Ashford B, Ranson M, Shannon K, Iyer NG, Ch'ng S, Low TH, Palme C, et al: Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies? J Clin Pathol. 73:17–22. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Yang L, Han S, Zhu J, Li Y, Wang Z, Fan YH, Lin E, Zhang R, Sahoo N, et al: Patterns of protein expression in human head and neck cancer cell lines differ after proton vs photon radiotherapy. Head Neck. 42:289–301. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Akali NR, Buggaveeti R, Sukumaran SV, Balasubramanian D, Iyer S and Thankappan K: Prior chemoradiotherapy and pathological perineural invasion predict the survival outcomes of salvage surgery in head and neck squamous cell carcinoma. Head Neck. 43:874–883. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ostuni R, Kratochvill F, Murray PJ and Natoli G: Macrophages and cancer: From mechanisms to therapeutic implications. Trends Immunol. 36:229–239. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ottria L, Candotto V, Cura F, Baggi L, Arcuri C, Nardone M, Gaudio RM, Gatto R, Spadari F and Carinci F: HPV acting on E-cadherin, p53 and p16: Literature review. J Biol Regul Homeost Agents. 32 (2 Suppl 1):S73–S79. 2018.PubMed/NCBI | |
|
Gau M, Karabajakian A, Reverdy T, Neidhardt EM and Fayette J: Induction chemotherapy in head and neck cancers: Results and controversies. Oral Oncol. 95:164–169. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Zhong X, Jiang H, Jiang H, Xie T, Tian Y, Li R, Wang B, Zhang J and Yuan Y: Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma. Aging (Albany NY). 12:22509–22526. 2020.PubMed/NCBI | |
|
Jeans C, Brown B, Ward EC, Vertigan AE, Pigott AE, Nixon JL and Wratten C: Comparing the prevalence, location, and severity of head and neck lymphedema after postoperative radiotherapy for oral cavity cancers and definitive chemoradiotherapy for oropharyngeal, laryngeal, and hypopharyngeal cancers. Head Neck. 42:3364–3374. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Miyauchi S, Kim SS, Pang J, Gold KA, Gutkind JS, Califano JA, Mell LK, Cohen EEW and Sharabi AB: Immune modulation of head and neck squamous cell carcinoma and the tumor microenvironment by conventional therapeutics. Clin Cancer Res. 25:4211–4223. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kim DY, Wu HG, Kim JH, Lee JH, Ahn SH, Chung EJ, Eom KY, Jung YH, Jeong WJ, Kwon TK, et al: Radiotherapy versus surgery in early-stage HPV-positive oropharyngeal cancer. Cancer Res Treat. 54:406–416. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Łasińska I, Kolenda T, Teresiak A, Lamperska KM, Galus Ł and Mackiewicz J: Immunotherapy in patients with recurrent and metastatic squamous cell carcinoma of the head and neck. Anticancer Agents Med Chem. 19:290–303. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tovar JM, Bazaldua OV, Vargas L and Reile E: Human papillomavirus, cervical cancer, and the vaccines. Postgrad Med. 120:79–84. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Solomon B, Young RJ and Rischin D: Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol. 52:228–240. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
de Ridder M, de Veij Mestdagh PD, Elbers JBW, Navran A, Zuur CL, Smeele LE and Al-Mamgani A: Disease course after the first recurrence of head and neck squamous cell carcinoma following (chemo)radiation. Eur Arch Otorhinolaryngol. 277:261–268. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Singh P, Bennett B, Bailey T, Taylor-Stokes G, Rajkovic I, Contente M, Curtis S and Curtis C: Real-world study of the impact of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) on quality of life and productivity in Europe. BMC Cancer. 21:8542021. View Article : Google Scholar : PubMed/NCBI | |
|
Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G Jr, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, et al: Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by prior cetuximab use. Clin Cancer Res. 25:5221–5230. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Billard-Sandu C, Tao YG, Sablin MP, Dumitrescu G, Billard D and Deutsch E: CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck. Eur Arch Otorhinolaryngol. 277:1273–1280. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Paget-Bailly S, Cyr D and Luce D: Occupational exposures and cancer of the larynx-systematic review and meta-analysis. J Occup Environ Med. 54:71–84. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yousefi H, Lak E, Mohammadi MJ and Shahriyari HA: Carcinogenic risk assessment among children and adult due to exposure to toxic air pollutants. Environ Sci Pollut Res Int. 29:23015–23025. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Dok R, Bamps M, Glorieux M, Zhao P, Sablina A and Nuyts S: Radiosensitization approaches for HPV-positive and HPV-negative head and neck squamous carcinomas. Int J Cancer. 146:1075–1085. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Guo F, Chang M, Scholl M, McKinnon B and Berenson AB: Trends in oropharyngeal cancer incidence among adult men and women in the United States from 2001 to 2018. Front Oncol. 12:9265552022. View Article : Google Scholar : PubMed/NCBI | |
|
Zolkind P, Lee JJ, Jackson RS, Pipkorn P and Massa ST: Untreated head and neck cancer: Natural history and associated factors. Head Neck. 43:89–97. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Valero C, Ganly I and Shah JP: Head and neck paragangliomas: 30-year experience. Head Neck. 42:2486–2495. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Pike LRG, Royce TJ, Mahal AR, Kim DW, Hwang WL, Mahal BA and Sanford NN: Outcomes of HPV-Associated squamous cell carcinoma of the head and neck: Impact of race and socioeconomic status. J Natl Compr Canc Netw. 18:177–184. 2020.PubMed/NCBI | |
|
Lach FP, Singh S, Rickman KA, Ruiz PD, Noonan RJ, Hymes KB, DeLacure MD, Kennedy JA, Chandrasekharappa SC and Smogorzewska A: Esophageal cancer as initial presentation of Fanconi anemia in patients with a hypomorphic FANCA variant. Cold Spring Harb Mol Case Stud. 6:a0055952020. View Article : Google Scholar : PubMed/NCBI | |
|
Saksø M, Mortensen LS, Primdahl H, Johansen J, Kallehauge J, Hansen CR and Overgaard J: Influence of FAZA PET hypoxia and HPV-status for the outcome of head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy: Long-term results from the DAHANCA 24 trial (NCT01017224). Radiother Oncol. 151:126–133. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou C and Parsons JL: The radiobiology of HPV-positive and HPV-negative head and neck squamous cell carcinoma. Expert Rev Mol Med. 22:e32020. View Article : Google Scholar : PubMed/NCBI | |
|
Larsen K, Rydz E and Peters CE: Inequalities in environmental cancer risk and carcinogen exposures: A scoping review. Int J Environ Res Public Health. 20:57182023. View Article : Google Scholar : PubMed/NCBI | |
|
Fishbein A, Hammock BD, Serhan CN and Panigrahy D: Carcinogenesis: Failure of resolution of inflammation? Pharmacol Ther. 218:1076702021. View Article : Google Scholar : PubMed/NCBI | |
|
Boffetta P, Hecht S, Gray N, Gupta P and Straif K: Smokeless tobacco and cancer. Lancet Oncol. 9:667–675. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hecht SS: Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer. 3:733–744. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Rumfield CS, Schlom J and Jochems C: Combination therapies for HPV-associated malignancies. J Clin Cell Immunol. 12:6082021. | |
|
Huang C and Zhan L: Network pharmacology identifies therapeutic targets and the mechanisms of glutathione action in ferroptosis occurring in oral cancer. Front Pharmacol. 13:8515402022. View Article : Google Scholar : PubMed/NCBI | |
|
Zandberg DP, Bhargava R, Badin S and Cullen KJ: The role of human papillomavirus in nongenital cancers. CA Cancer J Clin. 63:57–81. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Sun H, Zeng Q, Guo XJ, Wang H, Liu HH and Dong ZY: HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma. Sci Rep. 9:134042019. View Article : Google Scholar : PubMed/NCBI | |
|
Beddok A, Vela A, Calugaru V, Tessonnier T, Kubes J, Dutheil P, Gerard A, Vidal M, Goudjil F, Florescu C, et al: Proton therapy for head and neck squamous cell carcinomas: A review of the physical and clinical challenges. Radiother Oncol. 147:30–39. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ding L, Ren J, Zhang D, Li Y, Huang X, Hu Q, Wang H, Song Y, Ni Y and Hou Y: A novel stromal lncRNA signature reprograms fibroblasts to promote the growth of oral squamous cell carcinoma via LncRNA-CAF/interleukin-33. Carcinogenesis. 39:397–406. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE and Grandis JR: Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 6:922020. View Article : Google Scholar : PubMed/NCBI | |
|
Nathan CA, Khandelwal AR, Wolf GT, Rodrigo JP, Mäkitie AA, Saba NF, Forastiere AA, Bradford CR and Ferlito A: TP53 mutations in head and neck cancer. Mol Carcinog. 61:385–391. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Renken S, Nakajima T, Magalhaes I, Mattsson J, Lundqvist A, Arnér ESJ, Kiessling R and Wickström SL: Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress. J Immunother Cancer. 10:e0044582022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen SMY, Krinsky AL, Woolaver RA, Wang X, Chen Z and Wang JH: Tumor immune microenvironment in head and neck cancers. Mol Carcinog. 59:766–774. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Brand M, Laban S, Theodoraki MN, Doescher J, Hoffmann TK, Schuler PJ and Brunner C: Characterization and differentiation of the tumor microenvironment (TME) of orthotopic and subcutaneously grown head and neck squamous cell carcinoma (HNSCC) in immunocompetent mice. Int J Mol Sci. 22:2472020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang G, Zhang M, Cheng M, Wang X, Li K, Chen J, Chen Z, Chen S, Chen J, Xiong G, et al: Tumor microenvironment in head and neck squamous cell carcinoma: Functions and regulatory mechanisms. Cancer Lett. 507:55–69. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Assaf H, Erler D, Karam I, Lee JW, Higgins K, Enepekides D, Zhang L, Eskander A and Poon I: Stereotactic body radiotherapy for medically unfit patients with cancers to the head and neck. Head Neck. 42:2050–2057. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Evrard D, Szturz P, Tijeras-Raballand A, Astorgues-Xerri L, Abitbol C, Paradis V, Raymond E, Albert S, Barry B and Faivre S: Macrophages in the microenvironment of head and neck cancer: Potential targets for cancer therapy. Oral Oncol. 88:29–38. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Vengaloor Thomas T, Packianathan S, Bhanat E, Albert A, Abraham A, Gordy X, Kanakamedala M, Mehta D and Vijayakumar S: Oligometastatic head and neck cancer: Comprehensive review. Head Neck. 42:2194–2201. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Raudenska M, Balvan J and Masarik M: Cell death in head and neck cancer pathogenesis and treatment. Cell Death Dis. 12:1922021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen YP, Wang YQ, Lv JW, Li YQ, Chua MLK, Le QT, Lee N, Colevas AD, Seiwert T, Hayes DN, et al: Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: Implications for immunotherapy. Ann Oncol. 30:68–75. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wu P, Yuan G, Lu Z, Yang S, Zhu H, Zhou R, Wilson Wai SH, Cai J and Raymond King YT: Extracranial/intracranial vascular bypass to control carotid artery blowout in postirradiated nasopharyngeal carcinoma patients. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 35:448–452. 2021.(In Chinese). PubMed/NCBI | |
|
Pittet MJ, Michielin O and Migliorini D: Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol. 19:402–421. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
León X, Pujals G, Bulboa C, García J, López M and Quer M: Head and neck squamous cell carcinoma in cigar smokers. Distinctive epidemiological and prognostic characteristics. Acta Otorrinolaringol Esp (Engl Ed). 72:222–229. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Z, Wu B, Peng G, Xiao G, Huang J, Ding Q, Yang C, Xiong X, Ma H, Shi L, et al: Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma: A Single-Arm phase 2 clinical trial. Clin Cancer Res. 28:3268–3276. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Madhukar G and Subbarao N: Current and future therapeutic targets: A review on treating head and neck squamous cell carcinoma. Curr Cancer Drug Targets. 21:386–400. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Machiels JP, Tao Y, Burtness B, Tahara M, Licitra L, Rischin D, Waldron J, Simon C, Gregoire V, Harrington K, et al: Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. Future Oncol. 16:1235–1243. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, et al: Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet. 393:156–167. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hughes BGM, Munoz-Couselo E, Mortier L, Bratland Å, Gutzmer R, Roshdy O, González Mendoza R, Schachter J, Arance A, Grange F, et al: Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 Study): An open-label, nonrandomized, multicenter, phase 2 trial. Ann Oncol. 32:1276–1285. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wu J, Yuan Y and Tao XF: Targeted molecular imaging of head and neck squamous cell carcinoma: A window into precision medicine. Chin Med J (Engl). 133:1325–1336. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Rangabashyam MS, Lee SY, Tan SY, Mueller S, Sultana R, Ho J, Skanthakumar T, Tan NC, Tan HK, Soo KC and Iyer NG: Adherence of head and neck squamous cell carcinoma patients to tumor board recommendations. Cancer Med. 9:5124–5133. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Huang JJ, Geduldig JE, Jacobs EB, Tai TYT, Ahmad S, Chadha N, Buxton DF, Vinod K, Wirostko BM, Kang JH, et al: Head and neck region dermatological Ultraviolet-Related cancers are associated with exfoliation syndrome in a clinic-based population. Ophthalmol Glaucoma. 5:663–671. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Liang B, Tao Y and Wang T: Profiles of immune cell infiltration in head and neck squamous carcinoma. Biosci Rep. 40:BSR201927242020. View Article : Google Scholar : PubMed/NCBI | |
|
Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, et al: First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet. 398:27–40. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kochanek SJ, Close DA, Camarco DP and Johnston PA: Maximizing the value of cancer drug screening in multicellular tumor spheroid cultures: A case study in five head and neck squamous cell carcinoma cell lines. SLAS Discov. 25:329–349. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kang KH, Lebow ES, Niemierko A, Bussière MR, Dewyer NA, Daly J, McKenna MJ, Lee DJ, Loeffler JS, Busse PM and Shih HA: Proton therapy for head and neck paragangliomas: A single institutional experience. Head Neck. 42:670–677. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Guidi A, Codecà C and Ferrari D: Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: A systematic review. Med Oncol. 35:372018. View Article : Google Scholar : PubMed/NCBI | |
|
Ferris RL, Moskovitz J, Kunning S, Ruffin AT, Reeder C, Ohr J, Gooding WE, Kim S, Karlovits BJ, Vignali DAA, et al: Phase I Trial of cetuximab, radiotherapy, and ipilimumab in locally advanced head and neck cancer. Clin Cancer Res. 28:1335–1344. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Faur CI, Falamas A, Chirila M, Roman RC, Rotaru H, Moldovan MA, Albu S, Baciut M, Robu I and Hedesiu M: Raman spectroscopy in oral cavity and oropharyngeal cancer: A systematic review. Int J Oral Maxillofac Surg. 51:1373–1381. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Kao HF and Lou PJ: Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions. Head Neck. 41 (Suppl 1):4–18. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tao L, Zhou L, Zhang M, Wu H, Li X, Chen X, Li C, Shi Y, Cheng L and Lin H: Postoperative prognostic risk factors and treatment strategies for patients with T3-T4 hypopharyngeal squamous cell carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 35:400–404. 2021.(In Chinese). PubMed/NCBI | |
|
Okano S, Homma A, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, Ogawa T, Saito Y, Sano D, et al: Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck. Jpn J Clin Oncol. 51:173–179. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Ma Q, Yao R and Liu J: Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer. Int Immunopharmacol. 79:1060882020. View Article : Google Scholar : PubMed/NCBI | |
|
Mingo KM, Derakhshan A, Abdullah N, Chute DJ, Koyfman SA, Lamarre ED and Burkey BB: Characteristics and outcomes in head and neck sarcomatoid squamous cell carcinoma: The cleveland clinic experience. Ann Otol Rhinol Laryngol. 130:818–824. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wei C, Yang C, Wang S, Shi D, Zhang C, Lin X, Liu Q, Dou R and Xiong B: Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer. 18:642019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu XC, Ma SR, Shi S, Zhao YF and Jia J: Prognostic significance of lymph node ratio in patients with squamous cell carcinoma of the floor of the mouth. Int J Oral Maxillofac Surg. 51:307–313. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Varra V, Smile TD, Geiger JL and Koyfman SA: Recent and emerging therapies for cutaneous squamous cell carcinomas of the head and neck. Curr Treat Options Oncol. 21:372020. View Article : Google Scholar : PubMed/NCBI | |
|
Highland J, Aylward A, Do O, Monroe M and Buchmann L: Trust in physicians among patients with head and neck cancer before and after treatment. Head Neck. 43:2580–2588. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Tam S, Yao C, Amit M, Gajera M, Luo X, Treistman R, Khanna A, Aashiq M, Nagarajan P, Bell D, et al: Association of immunosuppression with outcomes of patients with cutaneous squamous cell carcinoma of the head and neck. JAMA Otolaryngol Head Neck Surg. 146:128–135. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang W, Green M, Choi JE, Gijon M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, et al: CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 569:270–274. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Valdes M, Villeda J, Mithoowani H, Pitre T and Chasen M: Inflammatory markers as prognostic factors of recurrence in advanced-stage squamous cell carcinoma of the head and neck. Curr Oncol. 27:135–141. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cristina V, Herrera-Gómez RG, Szturz P, Espeli V and Siano M: Immunotherapies and future combination strategies for head and neck squamous cell carcinoma. Int J Mol Sci. 20:53992019. View Article : Google Scholar : PubMed/NCBI | |
|
Chatterjee S, Kiyota N, Vaish R, Sharma A, Tahara M, Noronha V, Prabhash K and D'Cruz A: Weekly versus 3-weekly cisplatin along with radiotherapy for locoregionally advanced non-nasopharyngeal head and neck cancers: Is the equipoise in literature addressed yet? Head Neck. 45:1594–1603. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Dong L, Bi Q, Li X, Wu D, Ge X, Zhang X, Fu J, Zhang C, Wang C and Li S: Investigation of the efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating head and neck squamous cell carcinoma in mice. Target Oncol. 5:237–243. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ham JC, van Meerten E, Fiets WE, Beerepoot LV, Jeurissen FJF, Slingerland M, Jonker MA, Husson O, van der Graaf WTA and van Herpen CML: Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence. Head Neck. 42:828–838. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kaboli PJ, Zhang L, Xiang S, Shen J, Li M, Zhao Y, Wu X, Zhao Q, Zhang H, Lin L, et al: Molecular markers of regulatory T cells in cancer immunotherapy with special focus on acute myeloid leukemia (AML)-a systematic review. Curr Med Chem. 27:4673–4698. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jia T, Ming SX, Cao QQ and Xu FL: Combined treatment with acetazolamide and cisplatin enhances the chemosensitivity of human head and neck squamous cell carcinoma TU868 cells. Arch Oral Biol. 119:1049052020. View Article : Google Scholar : PubMed/NCBI | |
|
Ramalingam SS, Owonikoko TK and Khuri FR: Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin. 61:91–112. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Masarwy R, Kampel L, Horowitz G, Gutfeld O and Muhanna N: Neoadjuvant PD-1/PD-L1 inhibitors for resectable head and neck cancer: A systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 147:871–878. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kimura H, Hamauchi S, Kawai S, Onozawa Y, Yasui H, Yamashita A, Ogawa H, Onoe T, Kamijo T, Iida Y, et al: Pretreatment predictive factors for feasibility of oral intake in adjuvant concurrent chemoradiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck. Int J Clin Oncol. 25:258–266. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Rotman J, den Otter LAS, Bleeker MCG, Samuels SS, Heeren AM, Roemer MGM, Kenter GG, Zijlmans HJMAA, van Trommel NE, de Gruijl TD and Jordanova ES: PD-L1 and PD-L2 expression in cervical cancer: Regulation and biomarker potential. Front Immunol. 11:5968252020. View Article : Google Scholar : PubMed/NCBI | |
|
Brody RM, Albergotti WG, Shimunov D, Nicolli E, Patel UA, Harris BN and Bur AM: Changes in head and neck oncologic practice during the COVID-19 pandemic. Head Neck. 42:1448–1453. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jin Y and Qin X: Co-expression network-based identification of biomarkers correlated with the lymph node metastasis of patients with head and neck squamous cell carcinoma. Biosci Rep. 40:BSR201940672020. View Article : Google Scholar : PubMed/NCBI | |
|
Addeo A, Friedlaender A, Banna GL and Weiss GJ: TMB or not TMB as a biomarker: That is the question. Crit Rev Oncol Hematol. 163:1033742021. View Article : Google Scholar : PubMed/NCBI | |
|
Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A and Peters S: Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic. Ann Oncol. 30:44–56. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Park R and Park JC: Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer. Immunotherapy. 13:931–940. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Alsahafi E, Begg K, Amelio I, Raulf N, Lucarelli P, Sauter T and Tavassoli M: Clinical update on head and neck cancer: Molecular biology and ongoing challenges. Cell Death Dis. 10:5402019. View Article : Google Scholar : PubMed/NCBI | |
|
Maio M, Blank C, Necchi A, Di Giacomo AM, Ibrahim R, Lahn M, Fox BA, Bell RB, Tortora G and Eggermont AMM: Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now! Eur J Cancer. 152:155–164. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Hopkins-Rossabi T, Armeson KE, Zecker SG and Martin-Harris B: Respiratory-swallow coordination and swallowing impairment in head and neck cancer. Head Neck. 43:1398–1408. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrari M, Taboni S, Carobbio ALC, Emanuelli E, Maroldi R, Bossi P and Nicolai P: Sinonasal squamous cell carcinoma, a narrative reappraisal of the current evidence. Cancers (Basel). 13:28352021. View Article : Google Scholar : PubMed/NCBI | |
|
Long J, Wang D, Yang X, Wang A, Lin Y, Zheng M, Zhang H, Sang X, Wang H, Hu K and Zhao H: Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy. BMC Med. 19:1542021. View Article : Google Scholar : PubMed/NCBI | |
|
Kabzinski J, Maczynska M and Majsterek I: MicroRNA as a novel biomarker in the diagnosis of head and neck cancer. Biomolecules. 11:8442021. View Article : Google Scholar : PubMed/NCBI | |
|
Suzuki A, Kashiwagi N, Doi H, Ishii K, Doi K, Kitano M, Kozuka T, Hyodo T, Tsurusaki M, Yagyu Y and Nakanishi K: Patterns of bone metastases from head and neck squamous cell carcinoma. Auris Nasus Larynx. 47:262–267. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yu J, Smith J, Marwah R and Edkins O: Return to work in patients with head and neck cancer: Systematic review and meta-analysis. Head Neck. 44:2904–2924. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Patel JJ, Levy DA, Nguyen SA, Knochelmann HM and Day TA: Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis. Head Neck. 42:774–786. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
de Oliveira TB, Marta GN, de Castro Junior G and Kowalski LP: Induction chemotherapy for advanced oral cavity cancer. Curr Oncol Rep. 23:1292021. View Article : Google Scholar : PubMed/NCBI | |
|
Campo F, Zocchi J, Moretto S, Mazzola F, Petruzzi G, Donà MG, Benevolo M, Iocca O, De Virgilio A, Pichi B, et al: Cell-free human papillomavirus-DNA for monitoring treatment response of head and neck squamous cell carcinoma: Systematic review and meta-analysis. Laryngoscope. 132:560–568. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Lecocq M, Poncin A and Sautois B: Immunotherapy for head and neck squamous cell carcinoma. Rev Med Liege. 76:398–402. 2021.(In French). PubMed/NCBI | |
|
van de Goor R, van Hooren MRA, Henatsch D, Kremer B and Kross KW: Detecting head and neck squamous carcinoma using a portable handheld electronic nose. Head Neck. 42:2555–2559. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yan F, Lao WP, Nguyen SA, Sharma AK and Day TA: Elective neck dissection in salivary gland malignancies: Systematic review and meta-analysis. Head Neck. 44:505–517. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Qiang W, Dai Y, Xing X and Sun X: Identification and validation of a prognostic signature and combination drug therapy for immunotherapy of head and neck squamous cell carcinoma. Comput Struct Biotechnol J. 19:1263–1276. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Goto Y, Allevato MM, Wu VH, Saddawi-Konefka R, Gilardi M, Alvarado D, Yung BS, O'Farrell A, Molinolo AA, et al: Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. Nat Commun. 12:23832021. View Article : Google Scholar : PubMed/NCBI | |
|
Eckel HE and Bradley PJ: Treatment options for hypopharyngeal cancer. Adv Otorhinolaryngol. 83:47–53. 2019.PubMed/NCBI | |
|
Vasiliadou I, Breik O, Baker H, Leslie I, Sim VR, Hegarty G, Michaelidou A, Nathan K, Hartley A, Good J, et al: Safety and treatment outcomes of nivolumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma: Retrospective multicenter cohort study. Cancers (Basel). 13:14132021. View Article : Google Scholar : PubMed/NCBI | |
|
Leidner R, Crittenden M, Young K, Xiao H, Wu Y, Couey MA, Patel AA, Cheng AC, Watters AL, Bifulco C, et al: Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. J Immunother Cancer. 9:e0024852021. View Article : Google Scholar : PubMed/NCBI | |
|
Dua D, Kelly C, Kovarik J and Iqbal MS: The role of combining immunotherapy with primary (Chemo)radiotherapy in curative treatment settings of the head and neck cancer. Asia Pac J Clin Oncol. 18:e3–e10. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Van Wigcheren GF, De Haas N, Mulder TA, Horrevorts SK, Bloemendal M, Hins-Debree S, Mao Y, Kiessling R, van Herpen CML, Flórez-Grau G, et al: Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients. Oncoimmunology. 10:19355572021. View Article : Google Scholar : PubMed/NCBI | |
|
Semrau S, Gostian AO, Traxdorf M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Hautmann M, Klautke G, Laban S, et al: Implementation of double immune checkpoint blockade increases response rate to induction chemotherapy in head and neck cancer. Cancers (Basel). 13:19592021. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Fang Q, Du W, Zhang X, Dai L and Qiao Y: Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma. BMC Cancer. 21:6222021. View Article : Google Scholar : PubMed/NCBI | |
|
Niccoli Asabella A, Nappi AG, Trani O, Sardaro A and Rubini G: Heterogeneous response to immunotherapy in a patient with tonsillar squamous cell carcinoma assessed by 18F-FDG PET/CT. Diagnostics (Basel). 11:3482021. View Article : Google Scholar : PubMed/NCBI | |
|
Rothschild U, Muller L, Lechner A, Schlösser HA, Beutner D, Läubli H, Zippelius A and Rothschild SI: Immunotherapy in head and neck cancer-scientific rationale, current treatment options and future directions. Swiss Med Wkly. 148:w146252018.PubMed/NCBI | |
|
Kim MS, Malik NH, Chen H, Poon I, Husain Z, Eskander A, Boldt G, Louie AV and Karam I: Stereotactic radiotherapy as planned boost after definitive radiotherapy for head and neck cancers: Systematic review. Head Neck. 44:770–782. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Shibata H, Saito S and Uppaluri R: Immunotherapy for head and neck cancer: A paradigm shift from induction chemotherapy to neoadjuvant immunotherapy. Front Oncol. 11:7274332021. View Article : Google Scholar : PubMed/NCBI | |
|
Koukourakis IM, Giakzidis AG, Kouroupi M, Giatromanolaki A, Abatzoglou I, Karpouzis A and Koukourakis MI: Cutaneous squamous-cell carcinoma of the head-neck area refractory to chemo-radiotherapy: Benefit from anti-PD-1 immunotherapy. BJR Case Rep. 7:202001702021.PubMed/NCBI | |
|
Hyytiäinen A, Wahbi W, Väyrynen O, Saarilahti K, Karihtala P, Salo T and Al-Samadi A: Angiogenesis inhibitors for head and neck squamous cell carcinoma treatment: Is there still hope? Front Oncol. 11:6835702021. View Article : Google Scholar : PubMed/NCBI | |
|
Jagadeeshan S, Prasad M, Ortiz-Cuaran S, Gregoire V, Saintigny P and Elkabets M: Adaptive responses to monotherapy in head and neck cancer: Interventions for rationale-based therapeutic combinations. Trends Cancer. 5:365–390. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yang YM, Hong P, Xu WW, He QY and Li B: Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther. 5:2292020. View Article : Google Scholar : PubMed/NCBI | |
|
Yu S, Wang Y, He P, Shao B, Liu F, Xiang Z, Yang T, Zeng Y, He T, Ma J, et al: Effective combinations of immunotherapy and radiotherapy for cancer treatment. Front Oncol. 12:8093042022. View Article : Google Scholar : PubMed/NCBI | |
|
Huguet F, Durand B, Atallah S, Prébet C, Richard S and Baujat B: Combination of radiation therapy-immunotherapy for head and neck cancers: Promises kept? Cancer Radiother. 25:811–815. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Biau J and Bourhis J: Combining immunotherapy and radiotherapy in head and neck squamous cell cancers: Which perspectives? Curr Opin Oncol. 32:196–202. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang HQ, Fu R, Man QW, Yang G, Liu B and Bu LL: Advances in CAR-T cell therapy in head and neck squamous cell carcinoma. J Clin Med. 12:21732023. View Article : Google Scholar : PubMed/NCBI | |
|
Kosti P, Opzoomer JW, Larios-Martinez KI, Henley-Smith R, Scudamore CL, Okesola M, Taher MYM, Davies DM, Muliaditan T, Larcombe-Young D, et al: Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell Rep Med. 2:1002272021. View Article : Google Scholar : PubMed/NCBI | |
|
Huang J, Zheng M, Zhang Z, Tang X, Chen Y, Peng A, Peng X, Tong A and Zhou L: Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma. Cancer Immunol Immunother. 70:2453–2465. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Mei Z, Zhang K, Lam AK, Huang J, Qiu F, Qiao B and Zhang Y: MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma. Cancer Med. 9:640–652. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Vedvyas Y, McCloskey JE, Yang Y, Min IM, Fahey TJ, Zarnegar R, Hsu YS, Hsu JM, Van Besien K, Gaudet I, et al: Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Sci Rep. 9:106342019. View Article : Google Scholar : PubMed/NCBI | |
|
Soldierer M, Bister A, Haist C, Thivakaran A, Cengiz SC, Sendker S, Bartels N, Thomitzek A, Smorra D, Hejazi M, et al: Genetic engineering and enrichment of human NK cells for CAR-enhanced immunotherapy of hematological malignancies. Front Immunol. 13:8470082022. View Article : Google Scholar : PubMed/NCBI | |
|
Sridhar P and Petrocca F: Regional delivery of chimeric antigen receptor (CAR) T-cells for cancer therapy. Cancers (Basel). 9:922017. View Article : Google Scholar : PubMed/NCBI | |
|
Barata A, Hoogland AI, Kommalapati A, Logue J, Welniak T, Hyland KA, Eisel SL, Small BJ, Jayani RV, Booth-Jones M, et al: Change in Patients' perceived cognition following chimeric antigen receptor T-cell therapy for lymphoma. Transplant Cell Ther. 28:401.e72022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang G, Zhang Z, Zhong K, Wang Z, Yang N, Tang X, Li H, Lu Q, Wu Z, Yuan B, et al: CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Mol Ther. 31:134–153. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Haist C, Poschinski Z, Bister A, Hoffmann MJ, Grunewald CM, Hamacher A, Kassack M, Wiek C, Scheckenbach K and Hanenberg H: Engineering a single-chain variable fragment of cetuximab for CAR T-cell therapy against head and neck squamous cell carcinomas. Oral Oncol. 129:1058672022. View Article : Google Scholar : PubMed/NCBI | |
|
Plavc G and Strojan P: Combining radiotherapy and immunotherapy in definitive treatment of head and neck squamous cell carcinoma: Review of current clinical trials. Radiol Oncol. 54:377–393. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Botticelli A, Pomati G, Cirillo A, Mammone G, Ciurluini F, Cerbelli B, Sciattella P, Ralli M, Romeo U, De Felice F, et al: Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era. J Transl Med. 19:3032021. View Article : Google Scholar : PubMed/NCBI | |
|
Rajendra A, Noronha V, Joshi A, Patil VM, Menon N and Prabhash K: Palliative chemotherapy in head and neck cancer: Balancing between beneficial and adverse effects. Expert Rev Anticancer Ther. 20:17–29. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Choi JS, Sansoni ER, Lovin BD, Lindquist NR, Phan J, Mayo LL, Ferrarotto R and Su SY: Abscopal effect following immunotherapy and combined stereotactic body radiation therapy in recurrent metastatic head and neck squamous cell carcinoma: A report of two cases and literature review. Ann Otol Rhinol Laryngol. 129:517–522. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Davern M and Lysaght J: Cooperation between chemotherapy and immunotherapy in gastroesophageal cancers. Cancer Lett. 495:89–99. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W, Yan C, Gao X, Li X, Cao F, Zhao G, Zhao J, Er P, Zhang T, Chen X, et al: Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma. Oncologist. 26:e1110–e1124. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Altay-Langguth A, Balermpas P, Brandts C, Balster S, Ghanaati S, Winkelmann R, Burck I, Rödel F, Martin D, Rödel C and von der Grün J: Re-irradiation with concurrent and maintenance nivolumab in locally recurrent and inoperable squamous cell carcinoma of the head and neck: A single-center cohort study. Clin Transl Radiat Oncol. 28:71–78. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Patel B and Saba NF: Current aspects and future considerations of EGFR inhibition in locally advanced and recurrent metastatic squamous cell carcinoma of the head and neck. Cancers (Basel). 13:35452021. View Article : Google Scholar : PubMed/NCBI | |
|
Leu M, Patzer C, Guhlich M, Possiel J, Pilavakis Y, Schirmer MA, Rieken S and Dröge LH: Postoperative radiochemotherapy using modern radiotherapy techniques in elderly patients with head and neck squamous cell carcinoma: The challenge of weighing Up benefits and harms of treatment modalities in clinical practice. Cancers (Basel). 13:33842021. View Article : Google Scholar : PubMed/NCBI | |
|
Fang PQ, Gunther JR, Wu SY, Dabaja BS, Nastoupil LJ, Ahmed S, Neelapu SS and Pinnix CC: Radiation and CAR T-cell therapy in lymphoma: Future frontiers and potential opportunities for synergy. Front Oncol. 11:6486552021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Zhao Q, Zhang Y, Zhang Q, Zheng Z, Liu S, Liu Z, Meng L, Xin Y and Jiang X: Immunotherapy advances in locally advanced and recurrent/metastatic head and neck squamous cell carcinoma and its relationship with human papillomavirus. Front Immunol. 12:6520542021. View Article : Google Scholar : PubMed/NCBI | |
|
Patin EC, Dillon MT, Nenclares P, Grove L, Soliman H, Leslie I, Northcote D, Bozhanova G, Crespo-Rodriguez E, Baldock H, et al: Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade. J Immunother Cancer. 10:e0043062022. View Article : Google Scholar : PubMed/NCBI | |
|
Hecht M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Klautke G, Laban S, Hautmann MG, Brunner TB, Tamaskovics B, et al: Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer. J Immunother Cancer. 10:e0037472022. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng S, Fu L, Zhou P and Ling H: Identifying risk factors for the prognosis of head and neck cutaneous squamous cell carcinoma: A systematic review and meta-analysis. PLoS One. 15:e02395862020. View Article : Google Scholar : PubMed/NCBI | |
|
Jin WJ, Erbe AK, Schwarz CN, Jaquish AA, Anderson BR, Sriramaneni RN, Jagodinsky JC, Bates AM, Clark PA, Le T, et al: Tumor-specific antibody, cetuximab, enhances the in situ vaccine effect of radiation in immunologically cold head and neck squamous cell carcinoma. Front Immunol. 11:5911392020. View Article : Google Scholar : PubMed/NCBI | |
|
Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L and Liu X: Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J. 17:661–674. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, et al: The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 7:1842019. View Article : Google Scholar : PubMed/NCBI | |
|
Kordbacheh F and Farah CS: Molecular pathways and druggable targets in head and neck squamous cell carcinoma. Cancers (Basel). 13:34532021. View Article : Google Scholar : PubMed/NCBI | |
|
Myers JA and Miller JS: Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 18:85–100. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Yokota T, Homma A, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, Ogawa T, Saito Y, Sano D, et al: Immunotherapy for squamous cell carcinoma of the head and neck. Jpn J Clin Oncol. 50:1089–1096. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Boros A, Blanchard P, Dade A, Gorphe P, Breuskin I, Even C, Nguyen F, Deutsch E, Bidault F, Janot F, et al: Outcomes in N3 head and neck squamous cell carcinoma and role of upfront neck dissection. Laryngoscope. 131:E846–E850. 2021. View Article : Google Scholar : PubMed/NCBI |
